+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 53 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the use of PET imaging with the radioligand 18FPI-2620 to detect tau protein buildup in people with Alzheimers disease and control subjects. This open-label, multi-center, pivotal Phase 3 study compares imaging results during life to brain tissue analysis after death to assess the accuracy and safety of this diagnostic method. Participants will receive an intravenous injection of 18FPI-2620 at a dose of 185 MBq 20%. This study is non-randomized and single-group, focusing on the imaging procedure itself without placebo or alternative treatments. The study will continue until autopsy and brain tissue analysis are completed, with an average follow-up period of about one year. During the study, participants will undergo PET scans using 18FPI-2620. Researchers will assess the scans ability to correctly identify tau pathology related to Alzheimers disease by comparing them to post-mortem brain tissue analysis. The study includes safety monitoring and evaluation of the agreement between different readers interpreting the scans. Overall participation lasts until the participants death and brain autopsy, expected on average around one year after the scan.

Age: 50Years +All GendersPhase 3
25 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying a new vaccine called V118C to help prevent pneumococcal disease, which is caused by Streptococcus pneumoniae bacteria and can lead to infections in the lungs or other parts of the body. This trial focuses on toddlers and infants to evaluate the safety and tolerability of V118C. The study is a Phase 1, randomized, double-blind trial comparing V118C with an existing pneumococcal vaccine called PCV20 in children. The study has two stages. Stage 1 includes toddlers aged 12 to 15 months who have completed a 3-dose infant series of PCV20 these participants receive a single 0.5 mL injection of either V118C or PCV20. Stage 2 enrolls infants around 2 months old who receive four doses of either V118C or PCV20 at 2, 4, 6, and 12 months of age. All doses are given by intramuscular injection. The study monitors participants in both stages for up to 12 months after vaccination. During the trial, researchers will track immediate and longer-term side effects, both at the injection site and systemically, for up to one year post-vaccination. They will also measure immune responses using blood tests to assess antibody levels against pneumococcal bacteria. Participants will have scheduled visits for vaccinations and follow-up assessments to evaluate safety, immune response, and tolerability of the vaccines over the study period.

Age: 2Months - 15MonthsAll GendersPhase 1
15 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of Efimosfermin Alfa in adults with known or suspected metabolic dysfunction-associated steatohepatitis MASH at fibrosis stages F2 or F3. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how this drug affects participants with this liver condition. Participants will be randomly assigned to one of three groups receiving Efimosfermin Alfa at dose level 1, Efimosfermin Alfa at dose level 2, or a placebo. The treatment is administered as an injection, and the study will track effects and adverse events over 52 weeks. The study includes multiple assessments, including liver fibrosis measurements and blood tests to monitor liver health and other related factors. During the study, participants will undergo regular evaluations including blood tests, imaging scans, and clinical assessments up to Week 52 to monitor safety, liver function, and fibrosis changes. Researchers will measure treatment-emergent adverse events, laboratory abnormalities, and changes in liver fibrosis and fat content using various biomarkers and imaging techniques. This detailed monitoring helps assess the treatments impact and safety profile throughout the study period.

Age: 18Years - 75YearsAll GendersPhase 3
66 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
M

Actively Recruiting

Researchers are conducting a Phase 2 clinical trial to create a framework for evaluating the safety and effectiveness of multiple investigational treatments for chronic weight management in adults with obesity or overweight. This master protocol includes intervention-specific appendices ISAs that allow for independent evaluation of different treatments as they become available. Participants may receive various drugs, including LY3305677, LY3841136, tirzepatide, LY3549492, macupatide, eloralintide, or placebo. These treatments are administered either subcutaneously or orally, with each ISA detailing specific intervention plans. The study uses a randomized, double-blind, parallel design to assess these interventions. Participants will be involved in screening and treatment phases, with safety and efficacy monitored throughout. The primary outcome measures the number of participants allocated to each ISA from baseline to week 6. The study is sponsored by Eli Lilly and Company and plans to complete by February 2028, enrolling adults aged 18 to 75 years with obesity or overweight under controlled conditions.

Age: 18Years - 75YearsAll GendersPhase 2
57 locations
P

Actively Recruiting

Researchers are evaluating efimosfermin alfa in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis MASH and stage F2 or F3 liver fibrosis. The study aims to assess the safety and effectiveness of efimosfermin alfa compared to a placebo in resolving steatohepatitis and improving liver-related clinical outcomes. This Phase 3 trial is randomized, double-blind, and placebo-controlled, focusing on participants with specific liver conditions and metabolic syndrome components. Participants are assigned to one of three groups two groups receive different dose levels of efimosfermin alfa, while the third group receives a placebo. Treatments are given under controlled conditions, and the study follows a parallel design. The trial monitors participants at set intervals over a course of 52 weeks, with some outcomes tracked up to 48 months to evaluate long-term effects on liver fibrosis and steatohepatitis. During the study, participants undergo liver biopsies to confirm diagnosis and assess changes. Researchers evaluate improvements in fibrosis stage, steatohepatitis resolution, and various liver function measurements using imaging and blood tests. Safety is monitored by tracking adverse events and laboratory abnormalities. Quality of life and other health indicators are also assessed throughout the study, which lasts several years to capture both short- and long-term outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
91 locations
S

Actively Recruiting

Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.

Age: 18Years +All GendersPhase 2
205 locations
P

Actively Recruiting

The trial investigates the anti-tumor activity and safety of amivantamab administered as a subcutaneous co-formulation with recombinant human hyaluronidase PH20 rHuPH20 in participants with advanced or metastatic non-small cell lung cancer NSCLC, including those with EGFR mutations. It is a Phase 2, open-label study conducted by Janssen Research & Development, LLC, focusing on various patient cohorts defined by specific EGFR mutations and prior treatments. Participants receive amivantamab SC-CF injections at doses based on body weight and treatment cycle schedules, often combined with other drugs such as lazertinib, carboplatin, pemetrexed, or anticoagulants depending on their cohort and mutation status. Treatment cycles vary between 21 and 28 days, with dosing frequencies ranging from every two to four weeks. Eligible participants may enter a long-term extension phase to continue receiving study treatments. Throughout the study, participants undergo tumor assessments based on RECIST criteria, safety evaluations including adverse event monitoring and laboratory tests, and patient-reported outcome measures. The study tracks objective response rate, duration of response, progression-free survival, overall survival, and treatment satisfaction over periods extending up to several years. Regular visits include drug administration and clinical evaluations to monitor treatment effects and safety.

Age: 18Years +All GendersPhase 2
110 locations
E

Actively Recruiting

Researchers are studying ART0380, an investigational oral drug that targets ATR kinase, in people with advanced or metastatic solid tumors, including ovarian, peritoneal, fallopian tube, endometrial, colorectal, pancreatic, and acinar cell cancers. This open-label Phase IIIa trial aims to find the recommended dose of ART0380 alone and in combination with gemcitabine or irinotecan, to understand its side effects, and to evaluate its preliminary effectiveness in treating cancers that may have DNA repair defects or loss of ATM protein expression. Participants may receive ART0380 either alone or combined with gemcitabine or irinotecan in 21-day treatment cycles. ART0380 is given orally either intermittently or continuously, while gemcitabine is given on days 1 and 8, and irinotecan is infused on days 1 and 8 of each cycle. The study has multiple parts, including dose escalation phases and expansion cohorts targeting specific cancer types or genetic profiles. Some parts compare ART0380 plus gemcitabine to gemcitabine alone, while others explore ART0380 with irinotecan or as monotherapy. Throughout the study, participants will undergo regular assessments including imaging scans to evaluate tumor response by RECIST criteria, blood tests for tumor markers, and safety monitoring for side effects. Pharmacokinetics of ART0380 will be measured to understand drug levels and metabolism. Follow-up for progression-free survival and overall survival will continue for up to two years or more. Participants are expected to adhere to study visits and procedures, with performance status and organ function closely monitored during the trial.

Age: 18Years +All GendersPhase 1Phase 2
88 locations

1-10 of 53

1